Pregled bibliografske jedinice broj: 1049584
Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume
Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume // Medical Microbiology and Immunology, 208 (2019), 3-4; 415-429 doi:10.1007/s00430-019-00600-1 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 1049584 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' resume
Autori
Krmpotić, Astrid ; Podlech, Jürgen ; Reddehase, Matthias J. ; Britt, William J. ; Jonjić, Stipan
Izvornik
Medical Microbiology and Immunology (0300-8584) 208
(2019), 3-4;
415-429
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
Antibodies ; Cytomegalovirus ; Immunotherapy ; Latency ; Passive immunization ; Reactivation ; Recurrence ; Serum transfer ; Viral entry complexes ; Virus dissemination ; Virus spread ;
Sažetak
Cytomegaloviruses (CMVs) are highly prevalent herpesviruses, characterized by strict species specificity and the ability to establish non-productive latent infection from which reactivation can occur. Reactivation of latent human CMV (HCMV) represents one of the most important clinical challenges in transplant recipients secondary to the strong immunosuppression. In addition, HCMV is the major viral cause of congenital infection with severe sequelae including brain damage. The accumulated evidence clearly shows that cellular immunity plays a major role in the control of primary CMV infection as well as establishment and maintenance of latency. However, the efficiency of antiviral antibodies in virus control, particularly in prevention of congenital infection and virus reactivation from latency in immunosuppressed hosts, is much less understood. Because of a strict species specificity of HCMV, the role of antibodies in controlling CMV disease has been addressed using murine CMV (MCMV) as a model. Here, we review and discuss the role played by the antiviral antibody response during CMV infections with emphasis on latency and reactivation not only in the MCMV model, but also in relevant clinical settings. We provide evidence to conclude that antiviral antibodies do not prevent the initiating molecular event of virus reactivation from latency but operate by preventing intra-organ spread and inter-organ dissemination of recurrent virus.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE